日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

在未经治疗的套细胞淋巴瘤患者中，维奈托克联合来那度胺和利妥昔单抗治疗是安全有效的。

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2023009992
Phillips, Tycel J; Bond, David; Takiar, Radihka; Kump, Karson; Kandarpa, Malalthi; Boonstra, Philip; Mayer, Tera Lynn; Nachar, Victoria; Wilcox, Ryan A; Carty, Shannon A; Karimi, Yasmin H; Nikolovska-Coleska, Zaneta; Kaminski, Mark S; Herrera, Alex F; Maddocks, Kami; Popplewell, Leslie; Danilov, Alexey V
细胞生物学
淋巴瘤
发表日期：2023
文献求助 收藏

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

亚克隆TP53突变常见，并可预测滤泡性淋巴瘤对放射免疫疗法的耐药性。

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2022009467
Burack, W Richard; Li, Hongli; Adlowitz, Diana; Spence, Janice M; Rimsza, Lisa M; Shadman, Mazyar; Spier, Catherine M; Kaminski, Mark S; Leonard, John P; Leblanc, Michael L; Smith, Sonali M; Friedberg, Jonathan W
淋巴瘤
P53
免疫/内分泌
发表日期：2023
文献求助 收藏

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

鲁索替尼治疗成人继发性噬血细胞性淋巴组织细胞增生症：一项开放标签、单中心、试点试验

期刊:Lancet Haematology
影响因子:17.7
doi:10.1016/S2352-3026(19)30156-5
Ahmed Asra, Merrill Samuel A, Alsawah Fares, Bockenstedt Paula, Campagnaro Erica, Devata Sumana, Gitlin Scott D, Kaminski Mark, Cusick Alice, Phillips Tycel, Sood Suman, Talpaz Moshe, Quiery Albert, Boonstra Philip S, Wilcox Ryan A
细胞生物学
发表日期：2019
文献求助 收藏

Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States

美国学术机构治疗的血管内大B细胞淋巴瘤的多中心回顾性研究

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.15923
Geer, Marcus; Roberts, Emily; Shango, Maryann; Till, Brian G; Smith, Stephen D; Abbas, Hashim; Hill, Brian T; Kaplan, Jason; Barr, Paul M; Caimi, Paolo; Stephens, Deborah M; Lin, Emily; Herrera, Alex F; Rosenbaum, Evan; Amengual, Jennifer E; Boonstra, Philip S; Devata, Sumana; Wilcox, Ryan A; Kaminski, Mark S; Phillips, Tycel J
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2019
文献求助 收藏

Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

评估阿卡替尼在套细胞淋巴瘤治疗中的应用：设计、开发及治疗地位

期刊:Oncotargets and Therapy
影响因子:2.8
doi:10.2147/OTT.S155778
Girard, Jennifer; Reneau, John; Devata, Sumana; Wilcox, Ryan A; Kaminski, Mark S; Mercer, Jessica; Carty, Shannon; Phillips, Tycel J
细胞生物学
淋巴瘤
发表日期：2019
文献求助 收藏

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

Obinutuzumab联合CHOP方案对既往未接受治疗的晚期弥漫性大B细胞淋巴瘤有效且安全性良好：II期GATHER研究

期刊:Leukemia & Lymphoma
影响因子:2.2
doi:10.1080/10428194.2018.1515940
Sharman, Jeff P; Forero-Torres, Andres; Costa, Luciano J; Flinn, Ian W; Inhorn, Lowell; Kelly, Kevin; Bessudo, Alberto; Fayad, Luis E; Kaminski, Mark S; Evens, Andrew M; Flowers, Christopher R; Sahin, Deniz; Mundt, Kirsten E; Sandmann, Thomas; Fingerle-Rowson, Günter; Vignal, Charlotte; Mobasher, Mehrdad; Zelenetz, Andrew D
CHOP
免疫/内分泌
HOP
B细胞
淋巴瘤
细胞生物学
发表日期：2019
文献求助 收藏

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

在接受 CHOP 联合利妥昔单抗或 CHOP 联合 (131)I-托西莫单抗治疗的既往未接受治疗的滤泡性淋巴瘤患者中，疗效持续良好：III 期随机研究 SWOG-S0016 的长期随访

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2017.74.5083
Shadman, Mazyar; Li, Hongli; Rimsza, Lisa; Leonard, John P; Kaminski, Mark S; Braziel, Rita M; Spier, Catherine M; Gopal, Ajay K; Maloney, David G; Cheson, Bruce D; Dakhil, Shaker; LeBlanc, Michael; Smith, Sonali M; Fisher, Richard I; Friedberg, Jonathan W; Press, Oliver W
CHOP
HOP
淋巴瘤
发表日期：2018
文献求助 收藏

Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL)

原发性难治性外周T细胞淋巴瘤（PTCL）挽救治疗后的生存率

期刊:American Journal of Hematology
影响因子:9.9
doi:10.1002/ajh.24992
Zhang, Janie Y; Briski, Robert; Devata, Sumana; Kaminski, Mark S; Phillips, Tycel J; Mayer, Tera L; Bailey, Nathanael G; Wilcox, Ryan A
T细胞
T细胞
免疫/内分泌
淋巴瘤
细胞生物学
发表日期：2018
文献求助 收藏

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

对接受次全淋巴照射治疗的早期霍奇金淋巴瘤患者与接受化疗联合放疗的患者进行为期七年的能量/活力结局随访：SWOG S9133 及其生活质量相关研究 S9208

期刊:Journal of Cancer Survivorship
影响因子:2.9
doi:10.1007/s11764-016-0559-y
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A; Kornblith, Alice B; Gaynor, Ellen R; Bowers, Mindy Ann; Gatti, Gretchen S; Kaminski, Mark S; Erba, Harry Paul; Wang, Ting; Yoon, Jihye; Press, Oliver W; Fisher, Richard I
淋巴瘤
发表日期：2017
文献求助 收藏

Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma

超越剂量：利用治疗前生物标志物提高非霍奇金淋巴瘤放射免疫疗法疗效的剂量预测

期刊:Cancer Biotherapy and Radiopharmaceuticals
影响因子:2.1
doi:10.1089/cbr.2017.2182
Roberson, Peter L; Smith, Lauren B; Morgan, Meredith A; Schipper, Matthew J; Wilderman, Scott J; Avram, Anca M; Kaminski, Mark S; Dewaraja, Yuni K
淋巴瘤
免疫/内分泌
发表日期：2017
文献求助 收藏